In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.